Why Shares of MaxCyte Are Plummeting on Thursday
The biotech company reduced full-year guidance and expects so-so third-quarter revenue.
Nasdaq Futures Slip as Bond Yields Rebound, U.S. Jobs Report Looms
December Nasdaq 100 E-Mini futures (NQZ23) are trending down -0.10% this morning after three major U.S. benchmark indices closed higher on Wednesday as the latest batch of U.S. economic data prompted investors...
MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript
MXCT earnings call for the period ending June 30, 2022.
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md.,...